Amplidiag Easy, developed in partnership with Tecan, automates the nucleic acid extraction and PCR plate setup for all Amplidiag diagnostic products. © Mobidiag/Tecan

Molecular diagnostics specialist Mobidiag Ltd has got emergency approval for its Amplidiag® COVID-19 molecular diagnostic test in Finland.

New treatments against resistant Gram-negative bacteria, such as Pseudomonas aeruginosa, are the focus of a deal that Swiss pharma company Roche signed with US-based biotech company Forge Therapeutics in March. Source: CDC

With the coronavirus pandemic mounting, experts are warning of AMR as being the next, hidden crisis. 

Part of the phylogenetic tree published in PNAS. https://www.pnas.org/content/early/2020/04/07/2004999117. © Proc. Natl. Acad. Sci. USA

British researchers have tabled a phylogenetic tree showing different subtypes of SARS-CoV-2 developed in Asia, Europe and the US.

Source: Gomez

Every year, it’s the same: in January, investors are scratching their heads, searching to find investment ideas that could ensure the greatest return/performance. Given the current valuation, can 2020 deliver windfall surprises for European names?

Mark Beards is the new CEO of Sutura Therapeutics Ltd in Birkenhead (UK).

Lady with solnatide vials in production. © Apeptico

Austrian COVID-19 patients with severe lung dysfunction for the first time have a treatment option within a compassionate use program for Apeptico’s solnatide.

© Cytiva/GE Healthcare Life Sciences
Following the completion of Danaher’s €19.5bn take-over of GE Healthcare Life Sciences, GE’s CDMO arm is renamed Cytiva.
Pixabay.com/VSRao

Low intrinsic efficacy can explain the reduced side effects of new agonists of the m-opioid receptor a British-Australian reseach team reports.

In October 2019, Thierry Bernard provisionally took over the responsibilities of Qiagen CEO Peer Schatz, who had left the company unexpectedly after 27 years.

Austrian funding organisation FFG has launched €1m for COVID-19 projects, one of which is Apeptico's project. Furthermore, Apeptico gets funding under a Horizon 2020 grant of €47.5m for 17 COVID-19 projects. ©FFG

Austrian APEPTICO has got Horizon 2020 money for accelerated development and clinical use of Solnatide for the treatment of COVID-19 patients